Background/Aims: Peperomin E (PepE), a natural secolignan isolated from the whole plant of Peperomia dindygulensis, has been reported by ourselves and others to display potent anti-cancer effects in many types cancer cells, especially gastric cancer. However, the effects of PepE on the metastasis of poorly-differentiated gastric cancer cells and the underlying molecular mechanisms have not been well elucidated. Methods: We evaluated PepE effects on gastric cancer cell invasion and migration in vitro via wound healing and transwell assays and those on growth and metastasis in vivo using an orthotopic xenograft NOD-SCID mouse model. DNA methyltransferase (DNMT) activity was determined using a colorimetric DNMT activity/inhibition assay kit. PepE binding kinetics to DNMTs were determined using the biolayer interferometry binding assay. Gene and protein levels of DNMTs, AMPKα-Sp1 signaling molecules, and metastatic-suppressor genes in PepE-treated gastric cancer cells were determined using quantitative reverse transcription-PCR arrays and western blotting. The effect of PepE on Sp1 binding to the DNMT promoter was determined by electrophoretic mobilityshift assay. Global DNA methylation levels were determined using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. The methylation status of silenced metastatic-suppressor genes (MSGs) in gastric cancer cells was investigated by methylation-specific PCR. Results: PepE can dose-dependently suppress invasion and migration of poorly-differentiated gastric cancer cells in vitro and in vivo with low toxicity against normal cells. Mechanistically, PepE not only covalently binds to the catalytic domain of DNMT1 and inhibits its activity (IC 50 value 3.61 μM) but also down-regulates DNMT1, 3a, 
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Introduction
Gastric cancer (GC) is the fourth most common malignancy and remains the second leading cause of cancer-related death worldwide [1, 2] . Lacking early detection markers, GC is usually diagnosed in late stages, which, together with a deficit of effective therapeutic strategies, generally results in poor prognosis [1] [2] [3] [4] . Although chemotherapy and radiotherapy have been employed to treat GC, invasion and metastasis of cancer cells remains the main cause of GC related death, with a 5-year survival rate below 25% [5] . Therefore, identifying potential targets for attenuating the metastasis and developing potent therapeutic drugs are critical for effective GC treatment.
Traditional Chinese medicine (TCM) has been widely used to prolong the survival of patients with advanced GC and has become a popular complementary and alternative option for the treatment of malignant tumors owing to its demonstrated therapeutic efficacy and low side effects [6] [7] [8] [9] [10] . In particular, natural compounds derived from TCM show considerable promise in devising new chemotherapy drugs for use in patients with GC [10] [11] . Nevertheless, the detailed mechanisms by which TCM (or natural compounds derived therefrom) influences GC cell growth and metastasis remain to be elucidated.
Peperomia dindygulensis (Piperaceae) is commonly used in southern China as a complementary medicine to treat advanced/metastatic GC (Chinese name Shi-Chan-Cao) [12] . Chemical analysis of this plant has indicated that it contains various constituents including secolignans [13] [14] , tetrahydrofuran lignans [15] , flavonoids [16] , and polyketides [17, 18] . Secolignans are characteristic of the Peperomia species and have been shown to possess bioactivities that render them as effective treatments against tumors and inflammation [14, 19, 20] . Peperomin E (PepE) (Fig. 1 ), a secolignan characterized by an α-methylene-γ-butyrolactone moiety, has shown the strongest inhibition of tumor cell growth ability among the secolignans that have been isolated. Specifically, a previous study indicated that this molecule inhibited cell proliferation and induced apoptosis of GC cells in vitro and in vivo through mitochondrial and PI3K/Akt signaling pathways with relative safety, and thus has the potential to be used as a lead compound for further development as a chemotherapy agent against GC [21] . However, the effects and detailed mechanism of PepE on the inhibition of metastasis and invasion in GC cells have not yet been examined, as the primary clinical use of P. dindygulensis in China has targeted advanced/metastatic GC.
In previous decades, much effort has been made to identify prognostic biomarkers and drug targets in patients with advanced and metastatic GC [4] . As recently reported by multiple clinical studies, tumor cells require genetic and/or epigenetic changes in order to be transformed into metastatic cells [22] . DNA methylation, accomplished by a family of DNA methyltransferase (DNMT) enzymes, plays a critical role in epigenetic gene regulation in many forms of cancer including GC [23] [24] [25] [26] [27] . Moreover, the aberrant hypermethylation of a substantial number of metastatic-suppressor genes (MSGs), such as cadherins (i.e., E-cadherin) and tissue inhibitor of metalloproteinases (i.e., TIMP-3), has been widely investigated [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Increasing evidence has shown that E-cadherin and TIMP-3 are highly frequently methylated in tumor tissues from patients with advanced GC as well as in poorly differentiated GC cells (mainly owing to the overexpression of DNMTs in these cells), but not in adjacent normal tissues or normal cells, and that this, at least in part, leads to gene μL DMSO was added to each well and oscillated for 10 min. Absorbance at 490 nm was determined using a 96-well Multiskan Go microplate reader (Thermo-Fisher Scientific). Inhibition ratio (%) was calculated as [absorbance of control − absorbance of test sample)/absorbance of control] x 100%.
Wound healing assay GC cells were seeded into 12-well plates at a density of 5 x 10 5 /well. After 24 h, confluent monolayers were scratched with a 1 mL plastic pipet tip to create a uniform, cell-free area. Then, the cells in each well were incubated with serum free RPMI-1640 medium and treated with or without PepE at concentrations of 0.5, 1.0, and 2.0 μM for 24 h. Cells were photographed at time points 0 and 24 h using an Olympus CKX 41 inverted microscope (Tokyo, Japan). Digital images were acquired with a DP22 digital camera (Olympus) and the migrated cells to the denuded zone in microscopic fields (X 100) were counted and the mean count was calculated according to previously reported [48] .
Transwell migration and invasion assay
Cell migration and invasion were detected using Transwell chambers (Corning, Armonk, NY, USA) with a pore size of 8.0 μm in diameter. For the cell migration assay, the lower chamber was filled with 600 μL RPMI-1640 medium supplemented with 10% FBS, and the upper chamber was supplemented with 100 μL GC cell suspension at 1 x 10 5 cell/mL in RPMI-1640 medium without FBS, instead containing PepE at concentrations of 0, 0.5, 1.0, and 2.0 μM. After incubation at 37 °C for 24 h, the non-migrating cells (cells remaining on the upper side of the Transwell membrane) were carefully cleaned off with cotton swabs and migrating cells (cells accumulating on the lower side of the Transwell membrane) were fixed with 95% (v/v) ethanol for 5 min, and then stained with 5 mg/mL crystal violet for 5 min and observed using a microscope (X 200). Cells in six random microscopic fields were counted and the mean count was calculated.
For the cell invasion assay, the upper chamber was coated with 100 μL of 1:8 diluted Matrigel gel (BD Biosciences, San Jose, CA, USA). The lower chamber was filled with RPMI-1640 medium supplemented with 10% FBS. After the gel in the upper chamber was solidified, 200 μL GC cells (1 x 10 5 cells/mL) in RPMI-1640 medium containing PepE at concentrations of 0, 0.5, 1.0, and 2.0 μM was added to the upper chamber. After incubation at 37 °C for 48 h, the cells remaining in the upper chamber together with the gel were cleaned off carefully with cotton swabs and the invasive cells (cells accumulating on the lower side of the Transwell membrane) were fixed with 95% (v/v) ethanol for 5 min, and then stained with 5 mg/mL crystal violet for 5 min. Cells in six random microscopic fields (X 200) were counted and the mean count was calculated.
DNMT activity assay Nuclear extracts were prepared from NCI-N87, MGC-803, and HGC-27 cells using the Epiquik nuclear extraction kit (Epigentek) following the manufacturer's instructions and stored at −80 °C. The DNMT activity was determined using an Epiquik DNMT activity/inhibition assay kit (Colorimetric, Epigentek) following the manufacturer's instructions. Briefly, 10 μg nuclear extracts or 20 ng recombinant DNMT1, 3a, or 3b enzyme (purchased from New England Biolabs) was added to the sample wells coated with cytosine-rich DNA substrate. Then, different concentrations of PepE or 5-Aza-dC were added to the wells, with control wells receiving DMSO only. The substrate reaction was read spetro-photometrically at 450 nm using a 96-well microplate reader. Inhibition rates were calculated using the following formula, IC 50 was calculated from the dose-inhibition curves.
Percent activity (%) =

Molecular modeling
The three-dimensional (3D) structure of DNMT1 was obtained from the Protein Data Bank (PDB ID: 4WXX), comprising an X-ray structure with a 2.62 Å resolution of DNMT1 in complex with S-adenosyl-Lhomocysteine (SAH). The protein was prepared for docking by using the Protein Preparation Wizard in Discovery Studio version 4.0 (DS 4.0, Accelrys, San Diego, CA, USA). All crystallographic water molecules were deleted and a 15 radius grid (XYZ coordinates: −47.481, 61.396, 6.933) binding site was generated based on the previously reported catalytic domain of this protein. PepE was prepared using the Prepare Ligands module of DS 4.0 under the MMFF94x force field and a specifying pH value of 7.0. Several standard Cellular Physiology and Biochemistry
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procedures of DS CDOCKER docking protocols were performed. These docking procedures allowed ligand docking flexibility and a total of 10 top ranked structures were analyzed for studying receptor-ligand interactions between PepE and DNMT1.
Bio-layer Interferometry (BLI) binding assay
The binding kinetics of PepE to recombinant active human DNMT1 were determined using BLI on an Octet RED 96 system (ForteBio, Shanghai, China) following manufacturer protocol. All interaction analyses were performed at 25 °C in PBS plus 0.2% DMSO buffer. Purified recombinant DNMT1 was pre-labeled with biotin using a streptavidin (SA) conjugation kit (Abcam) according to manufacturer instruction. Loading of Dip and Read TM Streptavidin Biosensors (ForteBio) was conducted by exposing biotinylated DNMT1 (0.01 mg/mL) to biosensor tips for 2 h. The 96-well microplates used in the Octet were filled with 200 μL of sample or buffer per well and agitated at 1000 rpm. The loaded biosensors were washed in buffer for 600 s and transferred to wells containing PepE, 5-Aza-dC, and Peperomin A (PepA, secolignan isolated from Peperomia dindygulensis, which shares the same skeleton of PepE, except the α-methylene-γ-butyrolactone moiety is replaced by an α-methyl-γ-butyrolactone moiety) [14] at concentrations of 12.5, 25, 50, 100, and 200 μM in buffer, respectively. The association and dissociation was observed for 90 s for each sample diluent. Reference measurements were conducted by using buffer instead of PepE. A parallel set of SA unloaded biosensors was prepared to act as a control. The sample-sensorgrams were corrected by subtracting the double reference curve. Kinetic parameters (Kon and Koff) and affinity (K D ) were determined from a global fit to a 1:1 binding model of the data between DNMT1 and PepE, PepA, or 5-Aza-dC using Octet software (ForteBio).
Quantitative real-time reverse transcription-PCR assay
RNA was extracted from GC cells using the RNeasy RNA isolation kit (Qiagen, Hilden, Germany), and on-column DNA-digestion was performed using the RNase-free DNase Set (Qiagen). RNA (2 μg) was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol, and gene expression levels of DNMT1, DNMT3a, DNMT3b, E-cadherin, and TIMP3 were quantitatively measured in triplicate using a real-time quantitative PCR system (QuantStudio 3 RealTime PCR, Thermo-Fisher Scientific), using SYBR Green I (Applied Biosystems) and corresponding primers (Table S1 , designed by the software Primer premier 5.0 and synthesized by Genewiz Corp., Suzhou, China). The PCR conditions are listed in Table S2 . The mRNA levels of all tested genes were normalized against GAPDH, results are reported as fold change (2 −ΔΔCT ) relative to non-treated samples.
Methylation-specific PCR assay
Methylation-specific PCR was performed based on a previously described method. Briefly, DNA was extracted from PepE (0, 0.5, 1, and 2 μM) or 5-Aza-dC (2 μM)-treated GC cells using the DNeasy tissue kit (Qiagen) according to the manufacturer's instructions. Extracted DNA (1 μg) was modified with bisulfite using a CpGenome DNA modification Kit (Chemicon, Temecula, CA, USA). The modified DNA was amplified with primers for the methylated and unmethylated genes designed according to previously published reports (Table S3 ). The reactions were carried out using the Veriti 96 well thermal cycler (Applied Biosystems). The PCR conditions are listed in Table S4 . The PCR products were then loaded onto 3.5% low range agarose gels (Thermo-Fisher Scientific), stained with ethidium bromide, and observed under UV illumination using a Gel Doc XR Gel Documentation system (Bio-Rad).
Western blot analysis
The western blot was performed based on our previous studies. In brief, the lysates from the cultured GC cells (approximately 50 μg proteins) were separated on 10% sodium dodecyl sulfate polyacrylamide gels. Membranes (Abcam) were incubated with antibodies against DNMT1, DNMT3a, DNMT3b, E-cadherin, TIMP3, MMP-2, MMP-9, Sp1, AMPKα, p-AMPKα (Thr 172), and GAPDH (1:1000). The membranes were washed and incubated with the HRP-conjugated secondary antibodies. Subsequently, the membranes were transferred to freshly made ECL solution (Millipore, Waltham, MA, USA), followed by observing and documenting the signals under the Gel Doc XR Gel Documentation system (Bio-rad). Grey-levels were analyzed using Gel-pro 32 software (Media Cybernetics, Rockville, MD, USA) with normalization to GAPDH. Experiments were repeated three times. Electrophoretic mobility-shift assay (EMSA) EMSA was performed as previously described [49] [50] [51] . Briefly, oligonucleotide probes including DNMT1, DNMT3a (3A-P3-W1, DNMT3a 3 rd promoter), and DNMT3b (3B-P1-W1, DNMT3b 1 st promoter) promoter regions that contain putative Sp1-binding sites were chemically synthesized, and complementary oligos were annealed and labeled with 32 P-dCTP by Klenow fragment (Life Technologies, Carlsbad, SA, USA; the oligo sequences used in this study are previously reported by Liu et al. [49, 50] and Jinawath et al. [51] ). Nuclear extracts were prepared using an Epiquik nuclear extraction kit (Epigentek). EMSA with nuclear extracts and 32 P-labeled DNMT1, DNMT3a, and DNMT3b promoter oligos was performed as previously described [49] [50] [51] . For antibody super-shift assays, 4 μg Sp1 antibody or control rabbit IgG (Cell Signaling Technology, Mountain View, CA, USA) was added after the binding reactions proceeded 20 min, and further incubated for another 30 min before gel loading. Alternatively, nuclear extracts were pre-incubated with Sp1 antibody at 4 °C for 24 h before being added to the binding reactions.
Global DNA methylation analysis NCI-N87, MGC-803, and HGC-27 cells were treated with PepE at concentrations of 0, 0.5, 1, 2, or 4 μM or with 5-Aza-dC (1 μM) for 48 h. Genomic DNA was isolated and purified from the treated GC cells and tumor tissues extracted from the orthotopical in vivo studies (50mg/kg/d) using the DNeasy tissue kit (Qiagen, Valencia, CA, USA) following manufacturer instruction and stored at −80 °C. Global methylation levels were determined by liquid chromatography coupled with electrospray ionization tandem mass spectrometry as described previously by Song et al. [52] . Briefly, 0.5 μg genomic DNA was hydrolyzed to single nucleotides using the Epiquik one-step DNA hydrolysis kit (Epigentek, Farmingdale, NY, USA) following manufacturer instruction. Digested DNA was separated on a Prominence ultra-fast liquid chromatography system (Shimadzu, Kyoto, Japan) and determined on a triple quadrupole linear ion trap mass spectrometer equipped with a TurboIonSpray ion source (5500 Q-Trap, Applied Biosystems, Foster City, CA, USA). Quantification was undertaken in multiple reaction monitoring (MRM) mode by monitoring transition pairs as described by Song et al. [52] . Genomic DNA methylation was expressed as [5mdC]/[dG]%, which was quantified by using a calibration curve between the peak area ration of 5mdC to dG (
Treatment with small interfering RNAs (siRNA)
NCI-N87 cells were seeded in six-well culture plates in RPMI-1640 medium containing 5% FBS, and grown to 70% confluence prior to incubation with SiRNAs, Sp1 SiRNAs (No. sc-29487, Santa Cruz Biotechnology), DNMT1 SiRNAs (No. sc-35204, Santa Cruz Biotechnology) or control of SiRNA oligonucleotides (No. sc-37007, Santa Cruz Biotechnology) were transfected using the siRNA transfection reagent (No. sc-29528, Santa Cruz Biotechnology) according to the manufacturer's instructions and incubated with MEM medium (Gibco) for 30 min at room temperature before the mixture was added to the cells. After culturing for up to 30 h, the cells were washed and re-suspended in fresh medium for an additional 24 h for further experiment. RNAs and proteins from transfected NCI-N87 were extracted for further analysis.
Animal studies
Six-week-old female BALB/c athymic nude mice and NOD-SCID mice (obtained from the model animal research center of Nanjing University, Nanjing, China) were acclimated for 1 week and caged in groups of five. All animal studies were conducted under guidelines approved by the Animal Care and Use Committee of the Nanjing University of Chinese Medicine (Nanjing, China).
To investigate the antitumor effects of PepE, NCI-N87 cells (2x10
6
; 0.2 ml) were injected subcutaneously into the dorsal area of the BALB/c athymic nude mice. After 7 days, when tumors reached 5 mm in diameter, the mice were randomly assigned to two groups: (a) daily intra-gastric (i.g.) dose of soybean oil (control group, n = 5); and (b) daily i.g. 50 mg/kg of PepE (dissolved in soybean oil, n = 5). Mice were treated for 3 weeks. At the end of the treatment period, all mice were sacrificed, their tumor tissues were excised, weighed and placed in either 10% buffered formalin for paraffin fixation or frozen in liquid nitrogen for further observations.
To investigate the anti-metastatic activity of PepE in vivo, NCI-N87 cells tagged with luciferase reporter gene (NCI-N87-Luc) were orthotopic transplanted into the stomach of NOD-SCID mice according to previous reported methods [53, 54] . 6 days after transplantation, mice with NCI-N87-Luc tumor implants were subjected to bioluminescent analysis based on the luciferase signal. Briefly, mice were received 
Immunohistochemical observation
The tumor excised from in vivo experiment were fixed in 10% neutral formalin, embedded in paraffin, and cut into 4-μm thick sections. The tumor tissue sections were incubated in 3% hydrogen peroxide for 15 min and then in normal goat serum for 20 min to block endogenous peroxidase activity and nonspecific binding sites. Sections were incubated for 4 h with antibodies against DNMT1, DNMT3a, DNMT3b, E-cadherin, and TIMP3 (1:100 dilution), then treated with biotinylated secondary antibodies (1:200 dilution), and antibody-binding sites were visualized by 3, 3'-diaminobenzidine staining (Dako, Carpinteria, CA, USA). Sections were observed under an Olympus CKX 41 inverted microscope.
Statistical analysis
Statistical analyses were undertaken using GraphPad Prism 6.0 software (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA followed by Student's t-test was used for multiple comparison. P < 0.05 was considered significant and P < 0.01 was considered more significant.
Results
PepE inhibits proliferation, migration, and invasion of GC cells in vitro and in vivo
As we reported previously, PepE can inhibit cell proliferation and induce apoptosis of GC cells [21] . In the present study, we chose GC cell lines with reported metastatic abilities including the poorly differentiated cell line NCI-N87, MGC-803 and undifferentiated cell line HGC-27, to investigate the effects of PepE on proliferation, migration, and invasion abilities and correlated molecular mechanisms in these cells.
As depicted in Fig. 1A , the inhibitory effect of PepE on NCI-N87, MGC-803, and HGC-27 was dose-dependent, with IC 50 calculated as follows: NCI-N87, 1.3 μM; MGC-803, 1.9 μM, and HGC-27, 2.7 μM. Selectivity for tumor versus normal cells was determined by comparing the efficacy of PepE on the above cancer cells to its efficacy on the normal gastric epithelial cell line GES-1. PepE inhibitory effect on GES-1 was far less potent than that on the tumor cells (IC 50 value 76.1 μM), indicating that PepE is specific for cancer cells. An in vivo subcutaneously implantation of NCI-N87 cells in nude mice was used to examine the inhibiting effects of PepE on in vivo inhibition of GC cells. As shown in Fig. 1B , by i.g. administration of PepE at 50 mg/kg/d from day 7 after transplantation of NCI-N87 cells, tumor growth was significantly inhibited in PepE-treated group (P < 0.01). The inhibition rate was 60.3% after 3 weeks treatment.
Next, we investigated the effects of PepE on the migration of GC cells by means of a wound closure assay. As shown in Fig. 2A , relative wound closure was higher in control cells when compared with PepE-treated cells. Inhibition was observed when GC cells were incubated with PepE at different doses for 24 h treatment. Quantification analysis of cells migrated to the denuded zone demonstrated that the GC cell migration was significantly reduced in a dose-dependent manner, with migration ability reduced by 63.8%, 37.2%, and 15.9 % in NCI-N87 cells; 78.3%, 53.4% and 11.2% in MGC-803 cells; and 58.7%, 24.3%, and 9.4% in HGC-27 cells, as compared to the control group, when cells was incubated with 0.5, 1.0, and 2.0 μM PepE, respectively.
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To further confirm whether PepE inhibited the migration of GC cells, Transwell chamber experiments were used. As shown in Fig. 2B , PepE inhibited the migration ability of GC cells in a concentration-dependent manner. Quantification analysis indicated that migration ability reduced by 68.7%, 23.1%, and 18.1% in NCI-N87 cells; 61.3%, 37.1%, and 18.7% in MGC-803 cells; and 62.3%, 38.4%, and 31.2% in HGC-27 cells, as compared to the control group, when cells were incubated with 0.5, 1.0, and 2.0 μM PepE, respectively.
The effect of PepE on the invasion of GC cells was examined using Matrigel invasion chambers. As shown in Fig. 2B , compared to the untreated control, the number of invading cells represented by crystal-violet stain was markedly reduced in a dose-dependent manner in GC cells. Quantification analysis indicated that the inhibitory effects on cancer cell invasion, as measured by the percentage of control, were 62.5%, 27.1%, and 18.1% in NCI-N87 cells, 68.3%, 23.1%, and 17.9% in MGC-803 cells, and 62.7%, 28.9%, and 11.9% in HGC-27 cells, when treated with 0.5, 1.0, and 2.0 μM PepE, respectively.
Since PepE strongly attenuated migration and invasion of GC cells in vitro, we next examined the effect of PepE on metastasis of NCI-N87 cells in NOD-SCID mice xenograft model. To do this, we applied NCI-N87-Luc cells, which stably expresses constitutive luciferase and enable tumor growth and metastasis to be monitored by bioluminescent imaging. According to Fig. 3A , the luciferase light signal was detected 6 days after NCI-N87-Luc cell transplantation and the signal was mainly focus on the stomach region. The next day, mice were assigned to receive PepE treatment (50mg/kg) or soybean oil daily. According to Fig. 3A and 3B, tumor implants in the control group continued to grow and invade to other organs, giving out very strong bioluminescence signals after 35 days of tumor transplantation. In contrast, the PepE-treated group has no remarkable enhancement of luciferase signal. The signal intensity, as shown in Fig. 3A and 3B , was significantly weaker when compared to the control group (P<0.05 at 21 days and P<0.01 at 35 days of transplantation). This indicates that in the presence of PepE, the growth and metastasis of NCI-N87-Luc cells were significantly 
inhibited in vivo. At the end of the experiment, all mice were euthanized, organs including liver, spleen and kidney were carefully excised and imaged. The overall luciferase signal in the liver, spleen and kidney, representing the extent of metastasized NCI-N87-Luc cells, was found much stronger in control group than in PepE-treated group (P<0.05 in spleens, P<0.01 in livers and kidneys). This finding ensured that PepE treatment was effective in inhibiting the NCI-N87-Luc cells invade to the liver, spleen and kidney organs in orthotopic mice model.
PepE directly binds and inhibits DNMT1 activity
Transcriptional silencing of metastatic suppressor genes (MSGs) including E-cadherin and TIMP3 by DNA promoter hypermethylation plays a crucial role in the metastasis of advanced GC [38, 44] . This aberrant methylation is mainly attributed to the abnormal increased expression and activity of DNMTs, including DNMT1, DNMT3a, and DNMT3b in advanced/metastatic GC cells, which catalyze the transfer of methyl groups from S-adenosylmethionine to cytosines in CpG dinucleotides [22, 23, 25] . Therefore, DNMTs have been considered by researchers as promising therapeutic targets in treating the metastasis of advanced GC. 35 , livers, spleens and kidneys from both control and PepE-treated mice were excised and imaged, the bioluminescence signals of excised livers, spleens and kidneys were quantified for each group of mice. All data are presented as mean ± SD (n=5). *P<0.05, **P <0.01 when compared with control. 
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As we reported previously, we found that PepE suppressed DNMT activity in a dosedependent manner in A549 non-small lung cancer cells [55] , and we further confirmed this effect in poorly-differentiated GC cells. As depicted in Fig. 4A , we determined DNMT activity in the nuclear extract of NCI-N87, MGC-803, and HGC-27 cells after treatment with various concentrations of PepE. It was found that PepE inhibited DNMT activity in the GC cell extracts in a dose dependent manner, with IC 50 values of 2.44, 4.50, and 4.90 μM, respectively. To determine whether PepE could inhibit DNMT activity including DNMT1, DNMT3a, and DNMT3b in a cell free system, active recombinant DNMT1, DNMT3a, DNMT3b were added to the sample wells of the Epiquik DNMT activity/inhibition assay kit and treated with various concentrations of PepE, PepA (negative control) and 5-Aza-dC (positive control). Strikingly, as shown in Fig. 4B -F, we found a pronounced selectivity of PepE toward DNMT1 in the tested compound range with IC 50 value of 3.61 μM (the IC 50 value of 5-Aza-dC positive control against DNMT1 was determined as 1.08 μM, the IC 50 value of PepA negative control against DNMT1 was determined as 151.4 μM). Under these conditions, the enzymatic activity of DNMT3a and DNMT3b were slightly (IC 50 value of 96.3 μM against DNMT3a) or even not impacted by PepE.
To determine whether PepE could combine with DNMT1, we docked it in silico to the catalytic domain of DNMT1 (PDB ID: 4WXX, in complex with SAH) using the CDOCKER protocol in DS 4.0 as reported previously. Fig. 5A -C shows 3D and 2D representations of the optimized docked model of PepE with the catalytic site of DNMT1. Figure 5d shows the simulated bindings of PepE and the cofactor SAH onto the catalytic site of DNMT1. According to this binding model, the key binding site residues on DNMT1 included those that are within 5-Å reach of the bound PepE molecule (i.e., Cys 1148, Gly 1149, ASN 1578, Pro 1225, Cys 1226, Gln 1575, Glu 1168, Ser 1146, Asn 1578, and Ala 1579). Of these residues, eight are predicted to form H-bonds with PepE, including Cys 1148, Gly 1149, Asn 1578, Pro 1225, Gln 1575, Glu 1168, Ser 1146, and Asn 1578. In addition, the benzene rings of PepE form π-π stacking interactions with Asn 1578 and Ala 1579 of the DNMT1 catalytic site, which binds with DNMT1 in a similar manner as the aminopurine ring of SAH. Moreover, the α-methylene-γ-lactone moiety of PepE overlaps with the C-5 atom of the cytosine ring in the catalytic space. As the distance between the γ-C atom of the PepE and the C-5 of cytosine is only 1.3 Å, and these atoms are 5.3 and 4.3 Å away from the sulfhydryl group of the catalytic cysteine (Cys 1226), respectively, this model clearly indicated that PepE has the potential to inhibit the DNMT1 catalytic function through its α-methylene-γ-lactone by binding with its Cys 1226 through Michael-type addition. Notably, this is similar to that of the same moiety during parthenolide (a principal bioactive sesquiterpene lactone isolated from feverfew) binding with the DNMT1 catalytic domain [54] .
We thus explored the affinity binding kinetics of PepE with DNMT1 using BLI. Consistent with the results of the DNMT activity assay, PepE was found to bind directly to the DNMT1 protein in a dose dependent manner, as shown in Fig. 6 and Table 1 . The affinity equilibrium constant revealed a high affinity with K D value of 3.03 x 10 −5 M, which showed slightly lower affinity binding compared to 5-Aza-dC (K D = 1.52 x 10 −5 M). Nevertheless, the binding affinity was much lower between PepA (secolignan with an α-methyl-γ-lactone moiety instead of the α-methylene-γ-lactone moiety of PepE) and DNMT1 protein when compared with PepE in the tested compound concentration range, with a K D value only at 3.12 x 10 −2 M, which indicated that the α-methylene-γ-lactone moiety is critically important for PepE binding with DNMT1. Taken together, the above data indicate that PepE physically binds to the catalytic pocket of the DNMT1 protein to selectively inhibit DNMT1 activity.
PepE down-regulates DNMT1, 3a, and 3b expression in GC cells in vitro and in vivo
To determine whether PepE affected the protein expression levels of the DNMTs, we treated the above GC cells with different concentrations of PepE (1, 2, and 4 μM) and 0.1 μM of mithramycin (positive control) for 48 h. It was observed that PepE causes a dosedependent down-regulation in the protein levels of DNMT1, DNMT3a, and DNMT3b in both cell lines (Fig. 7A) . The ability of PepE to down-regulate DNMT expression was also evaluated 7B) showed that there was a significant decrease in DNMT1, DNMT3a, and DNMT3b levels in the tumor tissue sections of the PepE-treated group when compared to the control group in nude mice model (P<0.01). Next, we sought to determine whether the observed decline in DNMT1, DNMT3a, and DNMT3b protein levels was due to suppression of their gene expression upon PepE treatment. The mRNA levels of DNMTs were measured by quantitative real-time PCR. It was observed that PepE treatment significantly reduced the mRNA expression of DNMT1, DNMT3a, and DNMT3b, respectively, in a dose dependent manner (Fig. 7C) . The above results suggest a specific inhibitory activity of PepE on the expression of DNMT1, DNMT3a, and DNMT3b in tested GC cells both at the gene and protein level.
PepE represses transcription factor Sp1 expression and abrogates its DNA binding activity
Previous studies reported that DNMT1, DNMT3a and DNMT3b gene promoters contain Sp1 transcription factor binding sites, which regulate the expression and function of DNMTs in several cell systems [49, 50, 55, 56] . To support our hypothesis that Sp1 protein mediates DNMT expression in GC cell systems, Sp1 was knocked down using Sp1 SiRNA in NCI-N87 cells. A concurrent decrease in DNMT1, DNMT3a and DNMT3b was observed, thereby supporting the role of Sp1 protein in regulating DNMT expression in GC (Fig. 8A ). Next, we tested the changes of Sp1 after PepE treatment. As shown in Fig. 8B , PepE induced a dramatic decrease in Sp1 protein level in a dose-dependent manner in all tested GC cells; additionally, the Sp1 protein level was decreased in bortezomib (positive control, compound that inhibits Sp1 protein function and expression) -treated GC cells [49] .
To determine the effect of PepE on the Sp1 binding to the DNMT1, 3a, and 3b promoter, EMSAs were performed with nuclear extracts of NCI-N87 cells treated with PepE (2 μM for 24 h). As shown in Fig. 8C , PepE decreased the Sp1 protein binding to the gene promoters of DNMT1, 3a, and 3b, whereas obvious alteration of Sp1 DNA binding was also observed in bortezomib-treated [55] cells. Western-blot analysis showed that PepE decreased Sp1 protein expression in the same nuclear extracts (data not shown). 
PepE inhibits AMPKα-Sp1-DNMT signaling in GC cells
To further explore the action mechanism of PepE on Sp1 down-regulation, we examined the effect of PepE on the AMPK signaling pathway, which has been recently reported as being involved in mediating the expression of Sp1 [57, 58] . As described in Fig. 8D , PepE produced a significant increase in AMPKα phosphorylation in a dose dependent manner without affecting the level of total AMPKα. We then utilized an AMPK inhibitor to explore Fig. 8E , AMPK inhibitor (dorsomophin) treatment significantly reduced the level of p-AMPKα, which was found to dramatically increase the Sp1 protein expression in NCI-N87 cells; this activity was significantly attenuated in PepE-treated cells. The above all results suggested that PepE treatment led to the activation of p-AMPK, which in turn resulted in the down-regulation of Sp1 protein level and subsequent suppression of DNMT1 expression.
Decreases in DNMT1 transcription correlate with a decrease in migration and invasion of GC cells
To further elucidate the role of DNMT1 as the mediating factor in GC metastasis, a knockdown of DNMT1 with siRNA was executed in NCI-N87 cells (Fig. 9A) . As shown in Fig. 9B -C, DNMT1 knock-down significantly suppressed the cell migration and invasion in GC cells, which was similar to the effect of PepE. Moreover, our results demonstrated that 5-Aza-dC, a typical nucleotide DNMT1 inhibitor, also prevented the migration and invasion of NCI-N87 cells. Therefore, the above data suggested that the activity and expression of DNMT1 could directly regulate the metastasis of GC cells.
PepE treatment in GC cells reduces global DNA methylation in vitro and in vivo, thereby increasing expression of epigenetically silenced invasion-suppressor genes
Given the inhibitory effects of PepE on DNMT activity and transcription, we next investigated whether this compound also induced DNA hypomethylation. NCI-N87, MGC-803, and HGC-27 cells were treated with 0.5, 1.0, 2.0, or 4.0 μM of PepE or 1.0 μM of 5-Aza-dC for 24 h. Genomic DNA was isolated, hydrolyzed, and assessed for the levels of global DNA methylation by ultra-fast liquid chromatography-tandem mass spectrometry according to previous report [52] . Typical multiple monitoring ion chromatograms for dG and 5-mdC are shown in Fig. 10A . Calibration curves of 5-mdC and dG are shown in Fig. 10B (R 2 = 0.9993). Cellular Physiology and Biochemistry
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As shown in Fig. 10C , DNA methylation levels in GC cells treated with PepE and 5-Aza-dC were significantly lower than those in the untreated controls. Especially in MGC-803 cells, approximately 50% reduction in global DNA methylation was observed in PepE-treated (4.0 μM) cells compared with the untreated control. To test whether this effect could be reduced in vivo, DNA samples from NCI-N87 tumor tissues extracted from the nude mice were also analyzed by this methodology. We observed significant DNA hypomethylation in the tumor tissues from PepE-treated group compared with negative controls (P<0.05). This effect correlated with the aforementioned changes in DNMT activity and protein levels, suggesting that PepE acted as a hypomethylator both in vitro and in vivo by down-regulating DNMTs. The E-cadherin gene (also known as CDH1) is located on chromosome 16q22.1. E-cadherin constitutes an important invasion-suppressor gene that is frequently methylated and silenced in several cancers, especially in the poorly differentiated GC and diffuse histotype. Moreover, E-cadherin methylation is associated with poor prognosis of patients with GC, emphasizing its potential clinical significance [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . The TIMP3 gene is related to tumor development, in particular antagonizing the activity of metalloproteinases as well as inhibiting tumor growth, invasion, and metastasis. It has been reported that TIMP3 plays an invasion-suppressor function in GC. Moreover, TIMP3 is highly frequently methylated in GC cell lines and primary tumors, which leads to gene silencing. Notably, restoring TIMP3 expression in GC cells decreases tumor cell migration, further demonstrating its invasionsuppressor role in GC [44] [45] [46] [47] . Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry 2 or 4 μM treatment, this effect was even more significant (P < 0.01 when compared with untreated, Fig. 11A ). Quantitative real-time PCR analysis revealed that PepE and 5-AzadC each reactivated silenced E-cadherin mRNA expression in a concentration dependent manner in NCI-N87, MGC-803, and HGC-79 cells, respectively (i.e., >14-fold for NCI-N87, >17-fold for MGC-803, and >13-fold for HGC-27 cells at 4 μM PepE, Fig. 11C by left) . Similar findings were obtained for TIMP3. As shown in Fig. 11b , this gene was partially methylated in NCI-N87, MGC-803 and HGC-27 cells. After treatment of PepE, the level of unmethylated TIMP3 was significantly increased in these cells (P < 0.01 when compared with untreated, Fig. 11B ), The quantitative real-time PCR results demonstrated that the mRNA expression of TIMP3 was significantly restored in a dose dependent manner following PepE treatment (i.e., >11-fold for NCI-N87, >23-fold for MGC-803, and >18-fold for HGC-27 cells at 4 μM PepE, Fig.  11C by right) .
In vitro protein reactivation levels were determined using western blot analysis. As shown in Fig. 12A , PepE and 5-Aza-dC each significantly reactivated silenced E-cadherin in NCI-N87 cells in a concentration dependent manner. The protein levels of TIMP3 were also significantly restored in NCI-N87 cells in a dose dependent manner, followed by significant inhibition of a series of transduction signal proteins (MMP-2 and MMP-9) to elicit the antimetastatic activity (Fig. 12A) . Immunohistochemical analysis showed that there was a significant increase in E-cadherin and TIMP3-positive cells in the tumor tissues of PepEtreated mice when compared to the control group in NCI-N87 nude mice model (P < 0.01, Fig. 12B ). 
Discussion
GC is characterized by rapid emergence of systemic metastases, resulting in poor prognosis owing to limited curative treatment options. As response rates to current cytotoxic agents (i.e., platinum and 5-fluorouracil) are rather low, the outlook for patients with metastatic GC is very poor, with median survival ranging from 4 to around 12 months [1, [3] [4] [5] . Therefore, finding a new therapy for metastatic GC from TCM may expand our understanding of this disease and allow the development of new therapeutic drugs. Notably, our results from this study provide strong evidence that PepE, a naturally derived secolignan from the Chinese anticancer folk medicine P. dindygulensis, can effectively suppress proliferation and invasion/migration of poorly-differentiated GC cells in vitro and in vivo with low toxicity against normal cells.
Inhibition of cell proliferation and induction of anti-metastatic activity are controlled by various genes (proteins) and signaling pathways. Among these, E-cadherin and TIMP3 have been frequently reported as the key metastasis suppressor genes in cancer cells, particularly in GC. Increasing evidence indicates that the gene promoters of E-cadherin and TIMP3 are frequently hypermethylated in poorly differentiated GC whereas DNMTs are over-expressed, which leads to reduced gene expression or even gene silencing . Therefore, the inhibition of DNA methylation level is currently considered as a promising means of attenuating metastasis in human GC cells.
In the present study, we demonstrated that PepE is particularly effective in inhibiting DNMT1 activity (with IC 50 at 3.61 μM, although it is not active against DNMT3a and 3b) through physically binding to the protein (with K D value at 3.03 x10 -5 M). We then docked the compound to the catalytic pocket of DNMT1 and found that PepE could bind thereto, possibly in competition with cofactor SAH. Subsequently, the α-methylene-γ-lactone moiety of PepE may covalently bind with the thiol group of the Cys 1226 residue in the DNMT1 catalytic domain, thus inhibiting the enzyme activity. Furthermore, we also found in this study that PepE down-regulates the transcriptional level of DNMT1, 3a, and 3b, and inhibits their protein expression in a dose-dependent manner in tested GC cells. This occurs through disruption of the physical interaction of Sp1 with the DNMT1, 3a, and 3b promoter and through mediation of the AMPKα-Sp1 signaling pathway. Thus, the dual inhibitory activity of PepE; i.e., down-regulation of DNMT1, 3a, and 3b and covalent binding of the DNMT1 protein, underlies its comparable global DNA hypomethylation ability in the tested GC cell lines.
Notably, the global DNA methylation level of GC cells decreased significantly after exposure to PepE, with a similar in vivo hypomethylation activity in NCI-N87 orthotopic implantation NOD/SCID mice. Further examination of the reactivation of epigenetically reduced MSGs demonstrated that PepE also induces hypomethylation of the hypermethylated E-cadherin and TIMP3 gene promoters and enhances their expression in MGC-803, NCI-N87, and HGC-27 cells. Thus, it was clear that PepE blocks cell invasion and metastasis by epigenetic inhibition of DNMT function and reactivation of the hypermethylated MSGs in GC cells.
Over the past decades, two types of DNMT inhibitors have been discovered: nucleoside analogs and non-nucleoside compounds [59] . The former have been approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome and leukemia (i.e., 5-Aza-dC). However, such analogs need to be incorporated into DNA and serve as covalent inhibitors, with poor chemical stability, low specificity, and significant toxic side effects. In contrast, the non-nucleoside compounds with various chemical scaffolds have recently attracted much attention. Several natural products, such as genistein, laccaic acid A, and (-)-epigallocatechin-3-O-gallate (EGCG), were reported to inhibits DNMT activity. Unfortunately, the potency of these compounds is lower than that of the nucleoside analogs and their in vivo inhibitory activity against solid tumors is rarely reported [60] [61] . This situation prompts an urgent need to discover new-generation DNMT inhibitors with high in vitro and in vivo potency against tumors. 
Conclusion
Together, the findings of this study highlight PepE as an effective DNA methylation inhibitor via its dual functions of potentially binding to the catalytic site of DNMT1 and down-regulating the expression levels of DNMT1, 3a, and 3b through AMPKα-Sp1-DNMTs signaling (Fig. 13) . Thus, PepE appears to constitute a putative new-generation DNMT inhibitor as well as being a promising lead compound for the intervention of GC invasion/migration. Moreover, the findings are of importance for understanding the mechanisms of PepE anti-metastatic activity against GC cells. Further studies regarding the detailed mechanism of anticancer activity and structural modification analyses to increase the efficacy of this agent are ongoing.
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